دورية أكاديمية
أعرض في EDS

Hydralazine-augmented contrast ultrasound imaging improves the detection of hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Hydralazine-augmented contrast ultrasound imaging improves the detection of hepatocellular carcinoma.
المؤلفون: Sultan LR; Ultrasound Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Radiology, Children's hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Karmacharya MB; Department of Radiology, Children's hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Al-Hasani M; Ultrasound Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Cary TW; Department of Radiology, Children's hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Sehgal CM; Ultrasound Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
المصدر: Medical physics [Med Phys] 2023 Mar; Vol. 50 (3), pp. 1728-1735. Date of Electronic Publication: 2023 Jan 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley and Sons, Inc Country of Publication: United States NLM ID: 0425746 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4209 (Electronic) Linking ISSN: 00942405 NLM ISO Abbreviation: Med Phys Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017- : Hoboken, NJ : John Wiley and Sons, Inc.
Original Publication: Lancaster, Pa., Published for the American Assn. of Physicists in Medicine by the American Institute of Physics.
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/diagnostic imaging , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/diagnostic imaging , Liver Neoplasms*/pathology, Humans ; Rats ; Animals ; Contrast Media ; Ultrasonography ; Liver Cirrhosis ; Hydralazine/pharmacology
مستخلص: Background: Hepatocellular carcinoma (HCC) detection with B-mode and contrast-enhanced ultrasound (CUS) imaging often varies between subjects, especially in patients with background cirrhosis. Various factors contribute to this variability, including the tumor blood flow, tumor size, internal echoes, and its location in livers with diffuse fibro-cirrhotic changes.
Objective: Towards improving lesion detection, this study evaluates a vasodilator, hydralazine, to enhance the visibility of HCC by reducing its blood flow relative to the surrounding liver tissue.
Methods: HCC were analyzed for tumor visibility measured for B-mode, CUS, and hydralazine-augmented-contrast ultrasound (HyCUS) in an autochthonous HCC rat model. 21 tumors from 12 rats were studied. B-mode and CUS images were acquired before hydralazine injection. Rats received an intravenous hydralazine injection of 5 mg/kg, then images were acquired 20 min later. Four rats were used as controls. The difference in echo intensity of the lesion and the surrounding tissue was used to determine the visibility index (VI).
Results: The visibility index for HCC was found to be significantly improved with the use of HyCUS imaging compared to traditional B-mode and CUS imaging. The visibility index for HCC was 16.5 ± 2.8 for HyCUS, compared to 5.3 ± 4.8 for B-mode and 4.1 ± 3.8 for CUS. The differences between HyCUS and the other imaging modalities were statistically significant, with p-values of 0.001 and 0.02, respectively. Additionally, when compared to control cases, HyCUS showed higher discrimination of HCC (VI = 6.4 ± 1.2) with a p-value of 0.003, while B-mode (VI = 6.7 ± 1.4, p = 0.5) and CUS (VI = 6.4 ± 1.2, p = 0.3) showed lower discrimination.
Conclusion: Vascular blood flow modulation by hydralazine enhances the visibility of HCC. HyCUS offers a potential problem-solving method for detecting HCC when B-mode and CUS are unsuccessful, especially with background fibro-cirrhotic liver disease. Future evaluation of the approach in humans will determine its translatability for clinical applications.
(© 2023 American Association of Physicists in Medicine.)
References: J Ultrasound Med. 2011 Apr;30(4):495-9. (PMID: 21460149)
Mol Reprod Dev. 2015 Jul-Aug;82(7-8):518-29. (PMID: 26153368)
Phys Med Biol. 2013 Sep 21;58(18):6447-58. (PMID: 23999099)
Ultrasonography. 2017 Apr;36(2):160-169. (PMID: 28145108)
Oncol Res. 1999;11(4):179-85. (PMID: 10566616)
Ultrasound Med Biol. 2004 Feb;30(2):229-37. (PMID: 14998675)
Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785-9. (PMID: 2777668)
Radiother Oncol. 1990 Nov;19(3):281-91. (PMID: 2281156)
Gastrointest Radiol. 1989 Summer;14(3):255-61. (PMID: 2543605)
Biotechniques. 2021 Mar;70(3):181-185. (PMID: 33337254)
Ultrasonography. 2019 Jul;38(3):200-214. (PMID: 31006227)
Ultrasound Med Biol. 2013 Feb;39(2):187-210. (PMID: 23137926)
Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348. (PMID: 25135008)
Radiol Med. 2007 Feb;112(1):47-55. (PMID: 17310292)
Liver Cancer. 2015 Dec;4(4):241-52. (PMID: 26779444)
Ultrasound Med Biol. 2015 May;41(5):1287-93. (PMID: 25677641)
J Med Ultrason (2001). 2020 Apr;47(2):239-255. (PMID: 32170489)
Radiat Med. 1987 Jan-Feb;5(1):14-9. (PMID: 2819956)
Liver Cancer. 2014 Oct;3(3-4):458-68. (PMID: 26280007)
Radiol Med. 2010 Aug;115(5):714-31. (PMID: 20082225)
Biology (Basel). 2021 Jan 22;10(2):. (PMID: 33499069)
Dig Dis Sci. 1988 Jan;33(1):47-51. (PMID: 2448095)
Hepatol Int. 2017 Jul;11(4):317-370. (PMID: 28620797)
Ultraschall Med. 2008 Oct;29(5):499-505. (PMID: 19241506)
Nihon Shokakibyo Gakkai Zasshi. 1992 Jun;89(6):1360-8. (PMID: 1323723)
Invest Radiol. 2011 Feb;46(2):106-15. (PMID: 20938345)
Pediatr Nephrol. 2009 Oct;24(10):1939-49. (PMID: 17690916)
Radiographics. 2017 Nov-Dec;37(7):1994-2017. (PMID: 29131761)
Kidney Int. 2017 Jan;91(1):157-176. (PMID: 27692563)
Eur J Radiol. 2014 Mar;83(3):456-62. (PMID: 24387826)
Biomed Res Int. 2015;2015:349172. (PMID: 26090401)
World J Gastroenterol. 2008 Mar 21;14(11):1710-9. (PMID: 18350602)
World J Gastroenterol. 2014 Apr 7;20(13):3590-6. (PMID: 24707142)
Br J Cancer. 1995 Dec;72(6):1474-8. (PMID: 8519662)
Sci Rep. 2019 Jun 18;9(1):8708. (PMID: 31213661)
Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846)
PLoS One. 2014 Dec 22;9(12):e113586. (PMID: 25532146)
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):277-279. (PMID: 28162003)
Hepatology. 2011 Mar;53(3):1020-2. (PMID: 21374666)
Diagnostics (Basel). 2020 Aug 25;10(9):. (PMID: 32854253)
Magn Reson Med. 1996 Aug;36(2):204-11. (PMID: 8843373)
NMR Biomed. 1990 Aug;3(4):178-83. (PMID: 2206850)
معلومات مُعتمدة: R01 CA204446 United States CA NCI NIH HHS; R01 EB022612 United States EB NIBIB NIH HHS; EB022612-01 United States GF NIH HHS; CA204446-01 United States GF NIH HHS
فهرسة مساهمة: Keywords: cancer imaging; contrast-enhanced ultrasound; hepatocellular carcinoma; hydralazine; imaging biomarkers; tumor detection
المشرفين على المادة: 0 (Contrast Media)
26NAK24LS8 (Hydralazine)
تواريخ الأحداث: Date Created: 20230121 Date Completed: 20230321 Latest Revision: 20230426
رمز التحديث: 20230426
مُعرف محوري في PubMed: PMC10128060
DOI: 10.1002/mp.16232
PMID: 36680519
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-4209
DOI:10.1002/mp.16232